Itacitinib
- Generic Name
- Itacitinib
- Drug Type
- Small Molecule
- Chemical Formula
- C26H23F4N9O
- CAS Number
- 1334298-90-6
- Unique Ingredient Identifier
- 19J3781LPM
- Background
Itacitinib has been used in trials studying the treatment of Melanoma, Carcinoma, Metastatic Cancer, Endometrial Cancer, and B-cell Malignancies, among others.
The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy
- Conditions
- Other CancerBreast CancerGastrointestinal CancerNon Small Cell Lung Cancer
- Interventions
- Drug: Oncology DrugsDrug: Vismogedib
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- Fondazione per la Medicina Personalizzata
- Target Recruit Count
- 400
- Registration Number
- NCT04591431
- Locations
- 🇮🇹
I.R.S.T. Srl Irccs, Meldola, Italy
🇮🇹Ospedale Classificato Sacro Cuore - Don Calabria, Negrar, Italy
🇮🇹I.R.C.C.S. Istituto Oncologico Veneto, Padova, Italy
Itacitinib (INCB039110) and Extracorporeal Photopheresis (ECP) for First-Line Treatment in Chronic GVHD
- Conditions
- Chronic Graft-versus-host-disease
- Interventions
- Device: Extracorporeal Photopheresis (ECP)
- First Posted Date
- 2020-06-24
- Last Posted Date
- 2024-01-22
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 3
- Registration Number
- NCT04446182
- Locations
- 🇺🇸
Huntsman Cancer Institute at University of Utah, Salt Lake City, Utah, United States
Itacitinib in Advanced Hepatocellular Carcinoma
- Conditions
- Advanced Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2020-04-24
- Last Posted Date
- 2023-02-14
- Lead Sponsor
- Imperial College London
- Target Recruit Count
- 24
- Registration Number
- NCT04358185
- Locations
- 🇬🇧
Imperial College Healthcare NHS Trust, London, United Kingdom
Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation
- Conditions
- Acute LeukemiaMyelodysplastic SyndromeSecondary MyelofibrosisHematologic and Lymphocytic DisorderPrimary Myelofibrosis
- Interventions
- Other: Quality-of-Life AssessmentOther: Questionnaire Administration
- First Posted Date
- 2020-04-09
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 59
- Registration Number
- NCT04339101
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Itacitinib for the Treatment of Bronchiolitis Obliterans Syndrome After Donor Hematopoietic Cell Transplant
- Conditions
- Bronchiolitis Obliterans
- Interventions
- First Posted Date
- 2020-01-27
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 8
- Registration Number
- NCT04239989
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Study of IBI377 in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease
- Conditions
- GVHD,Acute
- Interventions
- First Posted Date
- 2020-01-07
- Last Posted Date
- 2020-10-29
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 1
- Registration Number
- NCT04220632
- Locations
- 🇨🇳
The First Affiliated Hospital of Suzhou University, Suzhou, Jiangsu, China
A Study of Itacitinib for the Treatment of Chronic Graft Versus Host Disease (cGVHD)
- First Posted Date
- 2019-12-16
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 15
- Registration Number
- NCT04200365
- Locations
- 🇺🇸
Texas Oncology - Sammons Cancer Center, Dallas, Texas, United States
🇺🇸Texas Transplant Institute, San Antonio, Texas, United States
🇺🇸Colorado Blood Cancer Institute, Denver, Colorado, United States
Itacitinib for the Prevention of Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplantation
- Conditions
- Allogeneic Stem Cell Transplant RecipientHematopoietic and Lymphoid Cell NeoplasmHematologic and Lymphocytic Disorder
- Interventions
- Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
- First Posted Date
- 2019-10-16
- Last Posted Date
- 2020-10-29
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT04127721
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Itacitinib and Tocilizumab for Steroid Refractory Acute Graft Versus Host Disease
- Conditions
- Steroid Refractory GVHDGraft Vs Host Disease
- Interventions
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2024-06-04
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 1
- Registration Number
- NCT04070781
- Locations
- 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States
🇺🇸Weill Cornell Medical College - New York Presbyterian Hospital, New York, New York, United States
A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy
- Conditions
- Cytokine Release Syndrome
- Interventions
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 112
- Registration Number
- NCT04071366
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Medical College of Wisconsin, Milwaukee, Wisconsin, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.